Protox licenses PRX321 from Neurocrine, PHS

Vancouver-based Protox Therapeutics has licensed targeted toxin therapeutics PRX321, a treatment for cancer, from Neurocrine Biosciences and the United States Public Health Service. PRX321 (formerly NBI-3001) is currently in Phase II clinical testing. The FDA has granted the drug both Fast Track designation and Orphan Drug Status for primary brain tumors. Protox will pay PHS and Neurocrine $2 million over the next three years and up to $4 million in milestones payments. plus royalties.

- take a look at this press release for more